Historical Background
The human BTG/Tob proteins form a small family of six proteins, which share a conserved N-terminal domain and antiproliferative activity (Matsuda et al. 2001; Tirone 2001; Winkler 2010). BTG2 was discovered first by two laboratories: as the immediate/early response gene PC3 in rat PC12 cells stimulated with nerve growth factor (NGF) and as TIS21 in mouse 3T3 fibroblasts in response to treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). The discovery of BTG1 (B-cell translocation gene 1) as a gene involved in a chromosomal translocation associated with chronic lymphocytic leukemia suggested the presence of a new family of antiproliferative genes. These findings were extended by the discovery of TOB1, which was found as an interacting protein of the ErbB2 tyrosine-kinase receptor (HER2). The remaining three members BTG3 (ANA), BTG4...
This is a preview of subscription content, log in via an institution to check access.
References
Ajima R, Akiyama T, Usui M, Yoneda M, Yoshida Y, Nakamura T, et al. Osteoporotic bone formation in mice lacking tob2: involvement of Tob2 in RANK ligand expression and osteoclasts differentiation. FEBS Lett. 2008;582:1313–8. doi:10.1016/j.febslet.2008.03.012. , S0014-5793(08)00241-X [pii]
Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev. 2006;20:236–52.
Ezzeddine N, Chang TC, Zhu W, Yamashita A, Chen CY, Zhong Z, et al. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol. 2007;27:7791–801.
Funakoshi Y, Doi Y, Hosoda N, Uchida N, Osawa M, Shimada I, et al. Mechanism of mRNA deadenylation: evidence for a molecular interplay between translation termination factor eRF3 and mRNA deadenylases. Genes Dev. 2007;21:3135–48.
Horiuchi M, Takeuchi K, Noda N, Muroya N, Suzuki T, Nakamura T, et al. Structural basis for the antiproliferative activity of the Tob-hCaf1 complex. J Biol Chem. 2009;284:13244–55.
Hosoda N, Funakoshi Y, Hirasawa M, Yamagishi R, Asano Y, Miyagawa R, et al. Anti-proliferative protein Tob negatively regulates CPEB3 target by recruiting Caf1 deadenylase. EMBO J. 2011;30:1311–23. doi:10.1038/emboj.2011.37. , emboj201137 [pii]
Matsuda S, Rouault J, Magaud J, Berthet C. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 2001;497:67–72.
Mauxion F, Chen CY, Seraphin B, Shyu AB. BTG/TOB factors impact deadenylases. Trends Biochem Sci. 2009;34:640–7. doi:10.1016/j.tibs.2009.07.008 , S0968-0004(09)00170-4 [pii]
Miyai K, Yoneda M, Hasegawa U, Toita S, Izu Y, Hemmi H, et al. ANA deficiency enhances bone morphogenetic protein-induced ectopic bone formation via transcriptional events. J Biol Chem. 2009;284:10593–600.
Ou YH, Chung PH, Hsu FF, Sun TP, Chang WY, Shieh SY. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007;26:3968–80.
Park S, Lee YJ, Lee HJ, Seki T, Hong KH, Park J, et al. B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/smad signaling. Mol Cell Biol. 2004;24:10256–62.
Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, et al. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet. 1996;14:482–6.
Stupfler B, Birck C, Seraphin B, Mauxion F. BTG2 bridges PABPC1 RNA-binding domains and CAF1 deadenylase to control cell proliferation. Nat Commun. 2016;7:10811. doi:10.1038/ncomms10811.
Suzuki T, J KT, Ajima R, Nakamura T, Yoshida Y, Yamamoto T. Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev. 2002;16:1356–70.
Tirone F. The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol. 2001;187:155–65.
Usui M, Yoshida Y, Tsuji K, Oikawa K, Miyazono K, Ishikawa I, et al. Tob deficiency superenhances osteoblastic activity after ovariectomy to block estrogen deficiency-induced osteoporosis. Proc Natl Acad Sci U S A 2004;101:6653–6658. doi:10.1073/pnas.0303093101, 0303093101 [pii].
Washio-Oikawa K, Nakamura T, Usui M, Yoneda M, Ezura Y, Ishikawa I, et al. Cnot7-null mice exhibit high bone mass phenotype and modulation of BMP actions. J Bone Miner Res. 2007;22:1217–23.
Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010;222:66–72. doi:10.1002/jcp.21919.
Yoshida Y, Nakamura T, Komoda M, Satoh H, Suzuki T, Tsuzuku JK, et al. Mice lacking a transcriptional corepressor Tob are predisposed to cancer. Genes Dev. 2003;17:1201–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media LLC
About this entry
Cite this entry
Almasmoum, H., Doidge, R., Winkler, G.S. (2016). BTG/TOB. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6438-9_272-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6438-9_272-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-6438-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences